CTOs on the Move

Cadence Neuroscience

www.cadenceneuro.com

 
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cadence Neuroscience raised $20M on 10/11/2019

Similar Companies

Kirin Pharma USA

Kirin Pharma USA, Inc. is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OrthoVirginia

OrthoVirginia is the state`s largest provider of expert orthopedic and therapy care which serves the needs of its patients through a team of highly trained specialists who are committed to the independent practice of medicine. Located in Lynchburg, northern Virginia and Richmond, OrthoVirginia has more than 100 physicians, 23 office locations, MRI facilities, outpatient surgery centers and physical therapy clinics. Its mission is to improve the musculoskeletal health and well-being of those who live in the communities that it serves. OrthoVirginia`s statewide network of physicians and healthcare providers strives to deliver high quality, cost effective orthopedic care to its patients.

A2 Biotherapeutics

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.

EMD Biosciences

EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.